Close Menu

NEW YORK – The GenomeWeb Index rose nearly 13 percent in July, as investors once again sought to reward companies that seemed to be making significant developments with their SARS-CoV-2 diagnostics.

The index outperformed the Dow Jones Industrial Average, the Nasdaq, and the Nasdaq Biotechnology Index, which rose 2 percent, 7 percent, and nearly 2 percent, respectively. Individual stock performances in the GenomeWeb Index were overwhelmingly positive in July, as 28 of the 32 stocks saw gains and only four saw losses.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.